

Good Clinical Practice (GCP) Key Topics

Jean Toth-Allen, Ph.D.

Office of Good Clinical Practice

FDA's Clinical Investigator Course Cosponsored by FDA's CDER, Office of Medical Policy and The Duke University School of Medicne

Food and Drug Administration

Topics

- Investigator responsibilities
- Clinical Investigator financial disclosure
- Expanded access to and charging for investigational drugs and devices
- Resources



- Both 21 CFR Part 312 and 812 hold the clinical investigator (CI) responsible for the conduct of the study at the study site
- Lack of appropriate study oversight by the CI is a commonly cited noncompliance in bioresearch monitoring (BIMO) inspections



- FDA final guidance document issued October 2009
- Guidance covers:
 - Appropriate delegation of study tasks
 - Appropriate training of study staff
 - Supervision of staff, including contracted personnel
 - Subject protections, including necessary medical care



- Appropriate delegation of study tasks
 - Any individual to whom a task is delegated must be qualified by education, training, and experience (and state licensure where relevant)
 - Individuals delegated must meet any protocol specified requirements
 - Listing of tasks and individuals delegated should be maintained



- Appropriate training of study staff
 - Familiarity with protocol and specific tasks
 - Knowledge of applicable regulations and HSP and GCP principles
 - Individuals competent or trained to cover tasks assigned
 - Updates and additional training provided as needed



- Supervision of staff, including contracted personnel
 - The level of supervision should be appropriate to the staff, the nature of the trial, and the subject population
 - A supervisory plan should include routine meetings with study staff and procedures for determining appropriate completion of delegated tasks
 - Oversight extends to SMO staff, CI-contracted providers (radiologists, labs), and medical device engineers



- Subject protections, including necessary medical care
 - Reasonable medical care for studyrelated medical problems
 - Provision of access to appropriate medical care when specialized care is required
 - Adherence to the study protocol



- 21 CFR Part 54 final regulation issued 1998
- Investigators and sub-investigators (those who play a significant role in the conduct of the study) are required to supply information (+ spouse and dependent children)
- Requires reporting to the study sponsor prior to participation in the study and updates yearly, as needed, until one year after study completion



- Requires applicant of a marketing application/permit to
 - Certify that there are no financial arrangements with each investigator or
 - Disclose specific financial arrangements with study investigators and what was done to minimize bias



Disclosable arrangements

- Compensation where the value could be affected by the study outcome (e.g., royalties)
- Significant Payments of Other Sorts (SPOOS) – i.e., not including the payments for conducting the study – to either the investigator or the institution (e.g., grants, equipment, retainers for on-going consultation, honoraria)



Disclosable arrangments (cont.)

- 3. Proprietary interest in the product, such as a patent, trademark, copyright, or licensing agreement
- 4. Equity interest in a publicly traded company whose value >\$50,000 or
 Equity interest such as ownership interest or stock options whose value cannot be readily determined through reference to public prices



- OIG inspection in 2009
- Recommended
 - Greater accountability of CIs, sponsors, and FDA
 - Additional guidance/training for FDA review staff
 - Follow-up during CI and sponsor inspections



- Revised draft guidance issued May 24, 2011; comment period closed July 25; final guidance in clearance
 - Addresses OIG concerns
 - FDA considering if information should be made publicly available
 - Requested comment and suggestions as to method for making the information public
 - Summary information in marketing approvals
 - Anonymous individual CI listing; group listings



Expanded access

- Long history of providing access outside of study participation
 - Emergency use
 - Treatment INDs/IDEs
- FDAMA (1997) provides for access to experimental therapies for individuals and small groups of patients with serious or immediately life-threatening diseases



Expanded access – investigational drugs

- August 13, 2009 final expanded access regulation issued
- Strives to balance competing issues
 - Access to unproven therapies for patients with serious or life-threatening diseases/conditions who have no satisfactory alternative
 - Potential to impede development and marketing of life-saving therapies
 - Minimizing risk to individuals



Expanded access – investigational drugs

- Regulation recognizes
 - primary goal is treatment
 - evidentiary standard necessary to support use varies by size of population:
 - Individual patients, including emergency use
 - Intermediate-size patient populations
 - Treatment IND or treatment protocol



- Removal of 312.7(d) + renaming 312.7 "Promotion of investigational drugs"
- Addition of 312.8 "Charging for investigational drugs under an IND"
- Changes/addition issued August 13, 2009, with expanded access regulations



Purpose of changes/additions:

- Provide clarity about circumstances under which charging in a clinical trial is permitted
 - Evidence drug has potential clinical benefit and a clinical trial is essential to demonstrating safety and effectiveness
 - Cost extraordinary due to manufacturing complexity, scarcity of a natural resource, large quantity needed, or some combination of the above



Purpose of changes/additions (cont):


- Set criteria for charging for all types of access described in new expanded access regulations
 - In general, reasonable assurance charging will not interfere with development of the drug for marketing approval
 - For treatment INDs and protocols
 - Assurance to include evidence of sufficient trial enrollment and adequate progress towards marketing
 - Required to submit development milestones for the following year
 - Authorization limited to a specified number of patients and for a maximum of 1 year, though a request for reauthorization is possible



Purpose of changes/additions (cont):

- Clarify what costs can be recovered
 - For a clinical trial only the direct costs of making the investigational drug available (manufacturing and/or acquiring and shipping and handling, not research and development or labor)
 - For expanded access cost of monitoring, complying with reporting requirements, and other administrative costs may be added to direct costs





*http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Howto MarketYourDevice/InvestigationalDeviceExemptionIDE/ucm051345.htm



Charging for investigational devices

- 21 CFR 812.7(b) prohibits a price larger than necessary to recover costs of manufacture, research, development, and handling
- 21 CFR 812.20(b)(8) IDE application to include amount to be charged and an explanation of why sale does not constitute commercialization of the device
- 21 CFR 812.(c)(1)(x) treatment IDE if device to be sold, application must include price, which is to be based on manufacturing and handling costs only



Resources

- Guidance for Industry, Investigator Responsibilities — Protecting the Rights, Safety, and Welfare of Study Subjects – final October 2009 – http://www.fda.gov/downloads/Drugs/Guid anceComplianceRegulatoryInformation/G uidances/UCM187772.pdf
- Financial Disclosure by Clinical Investigators, Guidance for Industry – http://www.fda.gov/RegulatoryInformation/ Guidances/ucm126832.htm



Resources

- Expanded access to and charging for investigational drugs
- http://edocket.access.gpo.gov/2009/p df/E9-19005.pdf
- http://edocket.access.gpo.gov/2009/p df/E9-19004.pdf
- Include preambles explaining rationale and comments received to proposed rules



HSP/GCP Resources

GCP website – http://www.fda.gov/ScienceRese arch/SpecialTopics/RunningClini calTrials/ default.htm



OGCP Staff

- Joanne Less, Ph.D., Director
- Janet Donnelly, CIP, RAC
- Bridget Foltz, MS, MT(ASCP)
- Sara Goldkind, M.D., M.A.
- Doreen Kezer, M.S.N.
- Marsha Melvin
- Kathleen (Swisher) Pfaender, R.N., J.D.
- Jean Toth-Allen, Ph.D.

